<--- Back to Details
First PageDocument Content
Medicine / Clinical medicine / Health / Rare diseases / RTT / Severe combined immunodeficiency / Hematopoietic stem cell transplantation / Lymphoproliferative disorders / Myelodysplastic syndrome / Gene therapy / Leukemia / B-cell chronic lymphocytic leukemia
Date: 2015-07-08 15:05:09
Medicine
Clinical medicine
Health
Rare diseases
RTT
Severe combined immunodeficiency
Hematopoietic stem cell transplantation
Lymphoproliferative disorders
Myelodysplastic syndrome
Gene therapy
Leukemia
B-cell chronic lymphocytic leukemia

Lifebank_Logo_withTag-centered

Add to Reading List

Source URL: www.lifebankusa.com

Download Document from Source Website

File Size: 440,87 KB

Share Document on Facebook

Similar Documents

MDACC LEUKEMIA AND LYMPHOMA Europe and the USA Linking Knowledge and Practice

DocID: 1vhjk - View Document

Genome-wide mapping of proviral integration sites in aggresive virus-induced leukemia Nicolas Rosewick1,2, Vincent Hahaut1, Maria Artesi1, Keith Durkin1, Ambroise Marçais3, Philip Griebel4, Natasa Arsic4, Véronique Ave

DocID: 1vcJH - View Document

Boswellic acid acetate induces apoptosis through caspase-mediated pathways in myeloid leukemia cells Lijuan Xia, Duo Chen, Rui Han, et al. Mol Cancer Ther 2005;4:Updated version

DocID: 1v6bB - View Document

The Dual E-selectin/CXCR4 Antagonist GMI-1359 Exerts Anti-leukemia Efficacy Against FLT3-ITDmutated Acute Myeloid Leukemia in A Patient-derived Xenograft Murine Model Mouse-1 Mouse-2

DocID: 1uSbg - View Document

A Phase I/II Study of GMI-1271, a Novel E-selectin Antagonist, in Combination with Induction Chemotherapy in Relapsed/Refractory and Previously Untreated Elderly Patients with Acute Myeloid Leukemia; Results to Date Dan

DocID: 1uJQ2 - View Document